
Novartis narrowed its mid-term sales growth outlook to 5% annually through 2031 at its London investor day, as patent expirations weigh on the Swiss drugmaker.
Download your eBook
Lifecycle Solutions: Positioning Pharmaceuticals For Commercial Success
Sponsored by TrialCard
Choose From:






